NCM
AVTX icon

Nantahala Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Nantahala Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4M Buy
1,862,250
+627,250
+51% +$9.92M 1.14% 17
2026
Q1 		$18.4M Hold
1,235,000
– – 0.68% 41
2025
Q4 		$22.4M Hold
1,235,000
– – 0.74% 30
2025
Q3 		$15.7M Buy
1,235,000
+240,000
+24% +$2.06M 0.55% 43
2025
Q2 		$4.97M Buy
995,000
+95,000
+11% +$444K 0.19% 92
2025
Q1 		$7.21M Buy
+900,000
New +$6.82M 0.29% 55
2023
Q3 		– Sell
-2,318
Closed -$198K – 135
2023
Q2 		$198K Sell
2,318
-1,052
-31% -$708K 0.02% 112
2023
Q1 		$1.42M Buy
3,370
+1,117
+50% +$880K 0.11% 86
2022
Q4 		$2.73M Sell
2,253
-30
-1% -$39.1K 0.18% 69
2022
Q3 		$1.82M Sell
2,283
-47
-2% -$51K 0.12% 76
2022
Q2 		$3.35M Sell
2,330
-48
-2% -$64.2K 0.17% 69
2022
Q1 		$4.8M Sell
2,378
-103
-4% -$259K 0.21% 65
2021
Q4 		$12.1M Buy
2,481
+67
+3% +$402K 0.43% 47
2021
Q3 		$15.2M Buy
2,414
+218
+10% +$1.77M 0.48% 50
2021
Q2 		$20.7M Sell
2,196
-461
-17% -$3.86M 0.59% 40
2021
Q1 		$23.1M Buy
2,657
+493
+23% +$4.66M 0.68% 37
2020
Q4 		$16.5M Buy
2,164
+153
+8% +$1.06M 0.51% 47
2020
Q3 		$13.2M Buy
2,011
+38
+2% +$286K 0.4% 56
2020
Q2 		$14.8M Buy
+1,973
New +$14.3M 0.45% 47

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Nantahala Capital Management's AVTX Position: Q2 2026 in Review

Nantahala Capital Management increased its Avalo Therapeutics (AVTX) stake by 51% in Q2 2026, buying an estimated $9.92M and bringing the position to 1,862,250 shares worth $34.4M. The position accounts for 1.14% of the portfolio, ranked #17.

Nantahala Capital Management first reported a position in AVTX in Q2 2020 and has held it in 19 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Nantahala Capital Management held 1,862,250 shares of Avalo Therapeutics worth $34.4M as of Q2 2026.
  • Nantahala Capital Management bought 627,250 Avalo Therapeutics shares in Q2 2026, an estimated $9.92M.
  • Avalo Therapeutics made up 1.14% of Nantahala Capital Management's portfolio in Q2 2026, its #17 holding.
  • Nantahala Capital Management first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.